Valneva SE

90 articles with Valneva SE

• Valneva Reports H1 2022 Results and Provides Corporate Updates

  8/11/2022

  Valneva SE, a specialty vaccine company, reported consolidated financial results for the first half of the year, ended June 30, 2022.

• Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15

  8/8/2022

  Pfizer Inc. and Valneva SE announced the initiation of a Phase 3 clinical study, Vaccine Against Lyme for Outdoor Recreationists, to investigate the efficacy, safety and immunogenicity of their investigational Lyme disease vaccine candidate, VLA15.

• Valneva Receives Marketing Authorization in Europe for Inactivated Whole-Virus COVID-19 Vaccine VLA2001

  6/24/2022

  Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Commission (EC) has granted marketing authorization in Europe for Valneva’s inactivated whole-virus COVID-19 vaccine, VLA2001, for use as primary vaccination in people from 18 to 50 years of age.

• Valneva Announces Successful Outcome of its AGM and Appointment of two New Supervisory Board Members

  6/24/2022

  ValnevaSE, a specialty vaccine company, announced that all the resolutions recommended by the Management Board were approved by the shareholders at its Annual General Meeting held yesterday in Paris.

• Valneva Receives Positive CHMP Opinion for Marketing Authorization of its Inactivated COVID-19 Vaccine Candidate in Europe

  6/23/2022

  Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization in Europe for Valneva’s inactivated whole-virus COVID-19 vaccine candidate, VLA2001, for use as primary vaccination in people from 18 to 50 years of age.

• Valneva and Pfizer Announce Closing of Equity Investment

  6/23/2022

  Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. (NYSE: PFE) today announced the closing of the equity investment announced on June 20, 2022.

• 

  Pfizer Buys Stake in Valneva to Advance Lyme Disease Vaccine

  6/20/2022

  Pfizer inked an Equity Subscription Agreement with France-based Valneva. They also updated their Collaboration and License deal for a Lyme disease vaccine that was announced in April.

• Valneva Joins Euronext’s Tech Leaders Index

  6/8/2022

  Valneva SE, a specialty vaccine company, announced its inclusion in the Euronext Tech Leaders Index which was launched yesterday by Euronext.

• Valneva to Present on its Single-Shot Chikungunya Vaccine Candidate, Host Symposium at NECTM8

  6/7/2022

  Valneva SE, a specialty vaccine company, announced it will present on its single-shot chikungunya vaccine candidate VLA1553 on June 9, 2022 at the 8th Northern European Conference on Travel Medicine in Rotterdam.

• Valneva to Present and Hold Investor Meetings at the Jefferies US Healthcare Conference

  6/3/2022

  ValnevaSE, a specialty vaccine company, announced that its senior management will present and participate in 1-on-1 meetings with institutional investors at the Jefferies Healthcare Conference which will take place from June 8 to 10, 2022 in New York.

• Valneva Successfully Completes Lot-to-Lot Consistency Trial for its Single-Shot Chikungunya Vaccine Candidate

  5/25/2022

  Valneva SE, a specialty vaccine company, announced the successful completion of the lot-to-lot Phase 3 trial of its single-shot chikungunya vaccine candidate, VLA1553.

• EMA Accepts Filing of Marketing Authorization Application for Valneva’s Inactivated COVID-19 Vaccine Candidate

  5/19/2022

  Saint Herblain, May19, 2022 – Valneva SE, a specialty vaccine company, confirmed that the European Medicines Agency has accepted the filing of a marketing authorization application for Valneva’s inactivated, whole-virus COVID-19 vaccine candidate, VLA2001.

• Valneva Receives Notice of European Commission’s Intent to Terminate COVID-19 Vaccine Purchase Agreement

  5/16/2022

  ValnevaSE announced that it has received a notice from the European Commission of intent to terminate the advance purchase agreement for Valneva’s inactivated whole-virus COVID-19 vaccine candidate VLA2001.

• Valneva Reports Q1 2022 Results and Provides Corporate Updates

  5/5/2022

  Valneva SE, a specialty vaccine company, reported its first quarter financial results ending March 31, 2022 and provided corporate updates.

• 

  Clinical Catch-Up: Genentech Announces Positive Data, Pfizer Develops New Vaccine

  5/2/2022

  A roundup of last week's top clinical trial updates and news.
• 

  Pfizer, Valneva Lyme Vaccine Shows Promise in Pediatric Patients

  4/26/2022

  Pfizer and its partner, Valneva, have announced positive Phase II data from its trial of vaccine candidate VLA15 in a pediatric population. VLA15 is intended to prevent Lyme Disease (LD).

• Valneva Announces Upsized Financing Arrangement with Leading US Healthcare Funds Deerfield and OrbiMed

  4/26/2022

  Valneva SE, a specialty vaccine company, announced an agreement to increase the principal amount of its existing $60 million debt financing agreement with funds managed by leading US-based healthcare investment firms Deerfield Management Company and OrbiMed.

• Valneva and Pfizer Report Positive Phase 2 Pediatric Data for Lyme Disease Vaccine Candidate

  4/26/2022

  Saint-Herblain and New York, April 26, 2022 – Valneva SE, a specialty vaccine company, and Pfizer Inc. reported positive Phase 2 pediatric data for their Lyme disease vaccine candidate, VLA15.

• Valneva Receives Conditional Marketing Authorization from UK MHRA for its Inactivated COVID-19 Vaccine

  4/14/2022

  Valneva SE announced that the Medicines and Healthcare products Regulatory Agency of the United Kingdom has granted Conditional Marketing Authorization for its inactivated whole-virus COVID-19 vaccine candidate, VLA2001, for primary immunization in adults 18 to 50 years of age.

• Valneva Reports Full Year 2021 Results and Provides Corporate Updates

  3/24/2022

  Saint-Herblain, March24, 2022 – Valneva SE, a specialty vaccine company, reported its audited consolidated financial results for the year ending December 31, 2021 and provided corporate updates.